Lv11
50 积分 2024-04-01 加入
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
4小时前
求助中
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
4小时前
已关闭
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
4小时前
已关闭
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
5个月前
已完结
Interleukin-10 in cancer immunotherapy: from bench to bedside
5个月前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
7个月前
已完结
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
7个月前
已完结
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
8个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer new england journal of medicine pdf
8个月前
已完结
皖公网安备34019202002308
